Introduction {#s1}
============

Osteoarthritis (OA) is a 00degenerative articular disease and is one of the most common di0sorders among the elderly ([@B54]). The major symptoms include pain, stiffness, swelling, tenderness, and joint movement disfunction, which has a serious impact on patients. Pain is the most prevalent symptom of OA ([@B17]). Unfortunately, current treatments only play a role in pain relief and symptoms control; as for the physical functional capacity improvement, radical therapy modalities have yet to appear ([@B53]). Statistically, over two thirds of adults have been affected by low-back pain (LBP) during their lifetime, and in some cases it may progress to a chronic state (lasts \>3 months), resulting in high rates of morbidity, disability, and productivity declines ([@B20]; [@B18]). Therapeutic measures for chronic LBP are therefore aimed at pain remission ([@B27]). Clinical therapeutics of both OA and chronic LBP is a difficult issue ([@B7]; [@B8]; [@B11]; [@B42]). Rehabilitation, pharmacological therapy, psychotherapy, and other modalities are recommended for many of these chronic pain conditions ([@B9]; [@B48]). Although pharmacotherapy is an important treatment approach, many medications are proven to give rise to drug-related adverse effects and complications, as well as other undesirable consequences ([@B26]; [@B34]). Therefore, there is an unmet need for an effective and safe resolution for chronic pain conditions.

For two decades, the growing investigation on nerve growth factor (NGF) and its relevant molecular targets has provided a completely original mode of disease therapeutics, especially for the treatment of chronic pain ([@B6]; [@B42]). It has been found that NGF may regulate pain through nociceptor sensitization ([@B32]; [@B31]). Levels of NGF have been found to be upregulated among peripheral nerve injury models in several preclinical studies ([@B52]; [@B51]; [@B12]; [@B21]; [@B55]). Clinically, concentrations of NGF are elevated in patients with a chronic pain state (e.g. osteoarthritis, chronic headaches, interstitial cystitis, pancreatitis, cancerous pain, diabetic neuropathy, etc.) ([@B50]; [@B51]; [@B6]). In rodent models, pain-related behaviors disappeared after the use of NGF antagonists ([@B45]; [@B28]; [@B51]), which provided rationale for the application of NGF antagonists to achieve significant relief of chronic pain. Furthermore, hyperalgesia and pain were reduced by the application of anti-NGF antibodies or IgG fusion proteins, both of which have the potential to inhibit NGF activities ([@B29]; [@B43]; [@B27]). Recent clinical studies presented promising outcomes for anti-NGF drugs in the treatment of OA and chronic LBP in human beings ([@B37]; [@B25]; [@B4]; [@B5]; [@B27]; [@B40]; [@B47]; [@B2]; [@B16]; [@B49]; [@B19]; [@B44]; [@B33]; [@B41]; [@B46]). Fasinumab, fulranumab, and tanezumab are three NGF-Abs undergoing clinical trials ([@B42]). Moreover, clinical trials of inflammatory pain relevant to OA and chronic LBP reported the most consistent efficacy in pain alleviation ([@B3]).

Based on the current clinical trials investigating anti-NGF agents, we endeavored to present more powerful evidence by synthesizing the results in a meta-analysis. The purpose of this meta-analysis was to study the efficacy of anti-NGF antibodies for the therapy of OA and chronic LBP and to provide a reference for the upcoming clinical trials associated with anti-NGF antibodies.

Materials and Methods {#s2}
=====================

Statement {#s2_1}
---------

All studies included in this meta-analysis had been published and declared ethical approval, and we did not collect or utilize any raw data of these results, therefore no ethical approval was needed for this meta-analysis study. This meta-analysis was conducted on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) ([@B35]).

Literature Search and Study Selection {#s2_2}
-------------------------------------

We systematically searched the databases PubMed, Embase, Wanfang Data, and China National Knowledge Infrastructure to retrieve studies from inception to November 30, 2019. Both Chinese and English language studies were considered. The following key terms were used for the database research: nerve growth factor antibody, fasinumab, fulranumab, tanezumab, osteoarthritis pain, OA, and chronic LBP. The references of the articles included were also searched in case of any additional studies not previously identified in the initial literature search.

Inclusion criteria of studies eligible for this meta-analysis were as follows: either full-texts or abstracts of randomized controlled trials (RCTs) that included patients with osteoarthritis pain and/or chronic low-back pain that evaluated the efficacy of anti-NGF agents. Outcomes included Western Ontario and McMaster Universities Arthritis Index (WOMAC) measures of pain, physical function, Patient's Global Assessment (PGA) ([@B10]), and rates of adverse events. Studies had to report at least one indicator assessed at the end of the intervention period or at a follow-up point after randomization. If studies recruited participants over the same period or in the same study centers, only the study with the maximum sample size or yielding the most pertinent outcomes was included to avert duplications. Exclusion criteria included case reports, review articles, news, conference abstracts with unavailable indicators, and editorials.

Two reviewers, Ziqi Ye and Yu Zhang, independently screened the titles of studies and checked the full-texts or abstracts for eligibility confirmation. When disagreement occurred, they discussed their arguments, and a third reviewer, Yu Huang, was involved in the case that no consensus was achieved.

Data Extraction and Quality Assessments {#s2_3}
---------------------------------------

Two reviewers, Si Yang and Lu Li, independently extracted data from the eligible studies including: study name, the studied pain condition, the sample size, the mean age of participants, the percentage of included women, content of the experimental and control intervention, and the indicators used in the study. Disagreements were checked by a third investigator, Yu Huang, until consensus was finally reached. As previously mentioned, mean alterations from baseline to check point in the WOMAC measures of pain, physical function, PGA Index, and difference of adverse events rates were indicators to be pooled.

The risk of bias in individual studies were assessed in seven domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias. Of note, other bias refers to "important concerns about bias not covered in the other domains in the tool" ([@B23]), they mainly include bias caused by early termination of a trial due to early benefit or to patients who were enrolled *via* unvalidated outcome measures or diagnostic criteria. They were evaluated by reviewers' empirical judgment according to the prescribed protocol of this study.

Statistical Analysis {#s2_4}
--------------------

We used the R 3.6.1 software and Review Manager 5.3 Software for statistical analyses. The standardized mean differences (SMD) or rate difference (RD) of outcomes, along with respective 95% confidence intervals (CIs), were calculated for each analysis. A Cochran Q test was used for heterogeneity evaluation between studies and an I² statistic was used to investigate the magnitude of the heterogeneity. The magnitude of heterogeneity was classified by the I² with: I² \> 25%, I² \> 50%, and I² \> 75% representing moderate, substantial, and considerable heterogeneity, respectively ([@B22]; [@B13]). We used a random-effects model or a fixed-effects model to calculate the pooled effects and their respective 95% CIs. The methods depended on: if I² value was \>50%, a random-effects model was used, otherwise a fixed-effects model was used. Sensitivity analysis was conducted in order to assess the stability of pooled outcomes. We used a Rosenberg's Fail-safe N approach to assess potential publication bias ([@B39]). A fail-safe number is defined as the number of studies with non-significance or that were unpublished that would be needed to be enrolled in a meta-analysis to turn a statistically significant result into non-significant one ([@B39]; [@B36]). Funnel plots were constructed to visualize possible asymmetry. A p value less than 0.05 was considered to be of statistical significance.

Results {#s3}
=======

Study Selection and Characteristics {#s3_1}
-----------------------------------

The literature search resulted in the identification of 646 publications ([**Figure 1**](#f1){ref-type="fig"}), from which 181 duplicates were removed and 295 articles were excluded as they were either animal experiments (70), abstracts with unavailable indicators (34), reviews (51), or topics not pertinent to the research question (140). After 170 full-text articles were screened, seven studies including 3890 participants were enrolled in this meta-analysis. All the articles were published in English, between 2013 and 2016. [**Table 1**](#T1){ref-type="table"} shows detailed characteristics of the clinical trials included.

![Flow chart of the literature search and study selection. The literature search and study selection procedure included four stages: literature identification through database searching based on the key terms, screening and study selection, eligibility confirmation, and enrollment of the final studies qualified for meta-analysis. In the identified 646 publications from database searching, 181 duplicates were removed and 465 records were further screened. As a result, 295 articles were excluded for reasons and the remaining 170 full-text articles were assessed for eligibility. Again, 163 studies were excluded for other reasons, and only seven studies including 3890 participants were eventually enrolled in quantitative synthesis.](fphar-11-00817-g001){#f1}

###### 

Characteristics of studies included in the meta-analysis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference   Pain condition   Sample size   Age, years       Female ratio (%)   Mean duration of OA or LBP, years   Intervention                                                     Outcomes
  ----------- ---------------- ------------- ---------------- ------------------ ----------------------------------- ---------------------------------------------------------------- ----------
  [@B27]      Chronic LBP      1052          51.7             52.9               10.9-12.3                           P, T 5 mg iv q8w, T 10 mg iv q8w, T 20 mg iv q8w, N 500 mg bid   W-P,\
                                                                                                                                                                                      W-PF,\
                                                                                                                                                                                      PGA

  [@B47]      OA               610           57.4             62.6               6.2-7.6                             P, T 5 mg iv q8w, T 10 mg iv q8w, O-CR 10-40 mg q12h             W-P,\
                                                                                                                                                                                      W-PF,\
                                                                                                                                                                                      PGA

  [@B2]       OA               604           62.4             77.7               6.1-6.7                             P+DSR^a^, T 2.5 mg+DSR, T 5 mg+DSR, T 10 mg+DSR                  W-P,\
                                                                                                                                                                                      W-PF,\
                                                                                                                                                                                      PGA

  [@B16]      OA               828           61.1 ± 10.1^b^   60.3               7.2-9.0                             P, T 5 mg iv q8w, T 10 mg iv q8w, N 500 mg bid                   W-P,\
                                                                                                                                                                                      W-PF,\
                                                                                                                                                                                      PGA

  [@B49]      OA               215           59.3 ± 8.7       68.8               NA^c^                               P, F 0.03 mg/kg, F 0.1 mg/kg, F 0.3 mg/kg                        W-P,\
                                                                                                                                                                                      W-PF,

  [@B33]      OA               196           59.4 ± 9.2       56.3               NA                                  P, F 3 mg q4w, F 9 mg q4w, O-CR bid                              W-P,\
                                                                                                                                                                                      W-PF,\
                                                                                                                                                                                      PGA

  [@B41]      OA               385           53.1 ± 12.0      54.0               NA                                  P, F 1mg q4w, F 3 mg q4w, F 6 mg q4w, F 10 mg q4w                PGA
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LBP, low-back pain; OA, Osteoarthritis; W-P, WOMAC Pain; W-PF, WOMAC Physical Function; PGA, Patient's Global Assessment; P, Placebo; T, Tanezumab; N, Naproxen; O-CR, Oxycodone-CR; F, Fasinumab; ^a^DSR, diclofenac sustained release; ^b^mean ± standard deviation; ^c^NA, not available.

Risk of Bias of Individual Studies {#s3_2}
----------------------------------

71% (5/7) of the studies included were evaluated with low risk in selection bias (random sequence generation), and only one study showed an unclear risk of bias in allocation concealment. Six of the seven studies showed low risk of performance bias. In regard to detection bias, only one study manifested an unclear risk in blinding of the outcome assessment. Six studies were assessed with low risk in attrition bias, and all the studies showed low risk of reporting bias. The risk of bias assessments is detailed in [**Figures 2**](#f2){ref-type="fig"} and [**3**](#f3){ref-type="fig"}.

![Risk of bias of individual studies. Five of the seven studies included were evaluated as "low risk" in selection bias (random sequence generation), and only one study showed an unclear risk of bias in allocation concealment. Six of the seven studies showed a low risk of performance bias, and only one study manifested an unclear risk in detection bias assessment. Six studies showed low risk in attrition bias and all the studies showed low risk of reporting bias.](fphar-11-00817-g002){#f2}

![Risk of bias summarized in percentage. 71% (5/7) of the studies included were evaluated with low risk in selection bias (random sequence generation) and 85.7% (6/7) of studies showed low risk for allocation concealment. 85.7% of studies showed low risk of performance bias and detection bias. 85.7% of studies were assessed with low risk in attrition bias and 100% the studies showed low risk of reporting bias.](fphar-11-00817-g003){#f3}

Assessment of Overall Effect Sizes {#s3_3}
----------------------------------

Six studies were assessed for the efficacy of anti-NGF agents on the change in the WOMAC pain Index. The result showed a significant reduction in the WOMAC pain Index (SMD = -2.22, 95% CI = -3.44 to -0.99, Z = -3.55, P = 0.0004; I^2^ = 99%). Six studies were tested for the effect of anti-NGF agents on the change in the WOMAC Physical Function Index. The result demonstrated a significant decrease (SMD = -2.76, 95% CI = -4.22 to -1.30, Z = -3.71, P = 0.0002; I^2^ = 99%). Furthermore, six studies detected the efficacy of anti-NGF agents on the change in the PGA Index. The result also showed a significant decrease in the PGA Index (SMD = -2.76, 95% CI = -4.42 to -1.09, Z = -3.24, P = 0.0012; I^2^ = 99%). The pooled effects on mean alterations in the WOMAC pain, the WOMAC physical function, and PGA Index are shown in [**Figures 4**](#f4){ref-type="fig"} **--** [**6**](#f6){ref-type="fig"}.

![Forest plot of changes from baseline to checkpoint in the WOMAC Pain subscale. Forest plot showing the pooled effects on mean alterations in the WOMAC pain Index. Six studies were assessed and the result showed a significant reduction in the WOMAC pain Index (I^2^ = 99%, P = 0.0004).](fphar-11-00817-g004){#f4}

![Forest plot of changes from baseline to checkpoint in the WOMAC Physical Function subscale. Forest plot showing the pooled effects on mean alterations in the WOMAC physical function subscale. Six studies were detected, and the result showed a significant reduction in the WOMAC physical function Index (I^2^ = 99%, P = 0.0002).](fphar-11-00817-g005){#f5}

![Forest plot of changes from baseline to checkpoint in the Patient's Global Assessment Index. Forest plot showing the pooled effects on mean alterations in the Patient's Global Assessment (PGA) Index. Six studies were tested and the result showed a significant reduction in the PGA Index (I^2^ = 100%, P = 0.0012).](fphar-11-00817-g006){#f6}

Adverse Events Incidence {#s3_4}
------------------------

The overall incidence of patients with adverse events was higher in the anti-NGF agents' therapy group than that in the control with a pooled rate difference of 0.11 (95% CI = 0.02 to 0.20, Z = 2.41, P = 0.016; I^2^ = 83%) ([**Figure 7**](#f7){ref-type="fig"}). Nausea, paresthesia, arthralgia, arthralgia, and headache were the five most frequently reported adverse events in anti-NGF treatment group among the seven studies included.

![Forest plot of differences of adverse events rates in experimental and control groups. In the seven studies included, the overall incidence rate of adverse events was higher in the anti-NGF treatment group than that of the control group, with a pooled rate difference of 0.11 (95% CI: 0.02 to 0.20) (I^2^ = 83%, P = 0.016).](fphar-11-00817-g007){#f7}

Sensitivity Analysis and Publication Bias {#s3_5}
-----------------------------------------

A sensitivity analysis was performed to investigate the impacts of single studies on the overall outcomes. After omitting each single study one after another, the pooled effects were not altered. The Rosenberg's fail-safe numbers were 8399, 12493, 13205, and 116 for WOMAC pain, physical function, PGA Index, and adverse events evaluation, which indicated that large numbers of unpublished and non-significant studies would be added to for the P value of the effect to attain \>0.05. Funnel plots were shown in [**Figure 8**](#f8){ref-type="fig"}.

![Funnel plots with pseudo 95% confidence limits. **(A)** Funnel plot of changes from baseline to checkpoint in the WOMAC Pain subscale. **(B)** Funnel plot of changes from baseline to checkpoint in the WOMAC Physical Function subscale. **(C)** Funnel plot of changes from baseline to checkpoint in the Patient's Global Assessment Index. **(D)** Funnel plot of differences of adverse events rates in the anti-NGF agent treatment group and control group.](fphar-11-00817-g008){#f8}

Discussion {#s4}
==========

Meta-analysis is considered to be a powerful and widely-used tool by pooling results from different studies with specific statistical methods to draw conclusions which can be more meaningful than individual reports alone ([@B38]; [@B30]). In this meta-analysis, seven published RCTs including 3890 participants with diagnosed OA pain and chronic LBP treated with anti-NGF antibodies were enrolled. The pooled results showed a significant reduction in the change of the WOMAC pain Index (P = 0.0004), WOMAC Physical Function Index (P = 0.0002), and the PGA Index (P = 0.0012). The results were consistent with preceding RCTs, which demonstrated that anti-NGF agents had a sounding effect on the relief of pain and function improvement in patients suffering from OA pain and chronic LBP. The underlying rationale may be that NGF plays a key role in the process of pain generation in chronic pain conditions ([@B1]; [@B14]; [@B15]) and anti-NGF antibodies have already revealed the potential to normalize nociceptive hyperactivity and produce pain alleviation in clinical settings, suggesting that these agents may play a role in pain treatment ([@B24]; [@B25]).

In this meta-analysis, two authors independently did a systematical database search in both the Chinese and English language to increase the potential of retrieving all relevant studies. Data extraction was also conducted by two independent investigators using a designed form. A Cochran Q test and an I² statistic were used to explore the magnitude of the heterogeneity. The results indicated considerable levels of heterogeneity that could not be ignored. We conducted a random effects model to perform the pooled analysis. The potential elements contributing to heterogeneity may probably include differences in the sample sizes of RCTs, the demographic features of the study participants, the locations of studies, the duration of disease, the specific types and dosage of medications, ways of giving drugs, and other relevant factors. We originally tried to explore the potential impact of moderator variables using meta regression in the study design. Nevertheless, the information we retrieved was not complete for this process. Sensitivity analysis revealed that the pooled results demonstrated the robustness of the outcomes in this meta-analysis. Funnel plots showed some asymmetry, which indicates there may be publication bias. However, the results of Rosenberg's fail-safe numbers calculation demonstrated that the publication biases (if they exist) may be theoretically ignored ([@B39]; [@B36]). We were not able to extract data from several articles with incomplete parameters, which may influence our conclusions.

In comparison to previous meta-analysis or RCTs investigating the effect of a certain anti-NGF antibody on pain relief, our current analysis focused on the 3 types of anti-NGF antibodies and included patients with OA pain and chronic LBP. The overall effects were in consistency with each individual study. The pooled incidence of adverse events was higher in the anti-NGF agents' treatment group than that in the control. The conclusion of this study may provide up-to-date evidence on chronic pain treatment for researchers and clinical practitioners in their fields of practice. Further clinical trials on anti-NGF antibodies will be continuously in need, and investigators should ensure rigorous methodology as well as controls for nonspecific therapy and therapist effects in order to reduce the risk of potential bias.
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